Expert Systems Marks Milestone: Lomonitinib Phase 1 Trials Completed in 3 Years

AI-driven drug discovery firm Expert Systems has reached a key milestone in collaboration with Eilean Therapeutics, having completed a Phase 1 clinical trial for lomonitinib, a targeted pan-FLT3/IRAK4 inhibitor. The trial showed the drug had a strong safety profile with no major side effects at effective doses, making it a promising candidate for treating FLT3-mutated Acute Myeloid Leukemia (AML). The company has also initiated a multiple ascending dose Phase 1 study, showcasing the rapid progression of lomonitinib from concept to clinical testing within a three-year timeframe.
Lomonitinib is designed to inhibit FLT3 mutations, which are common in AML, and overcome resistance mechanisms that current FLT3 inhibitors face. The drug has shown potential in blocking both the "gatekeeper" mutation and the IRAK4 escape pathway, offering hope for patients with resistant forms of the disease.
Eilean Therapeutics, backed by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, is focused on developing innovative therapies for hematologic and solid cancers. They are utilizing Expert Systems' advanced AI platform to accelerate the drug discovery and development process.
Expert Systems operates an AI-based platform that encompasses all stages of preclinical drug discovery and early development, from target identification to toxicology assessments. The company has played a significant role in the establishment of numerous startups and has overseen more than 30 R&D programs globally.
Eilean Therapeutics is a biopharmaceutical company that aims to identify novel small molecule inhibitors for cancer treatment. They are dedicated to creating groundbreaking treatments for patients with various types of cancer, utilizing their AI platform and the expertise of their partners to advance the field of targeted cancer therapy.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!